Skip to main content

New Development Chief at Celera Genomics; NuGEN Builds its Board; Los Alamos Launches Homeland Security Center

NEW YORK, Dec. 18-Celera Genomics said yesterday that it had appointed James Yee as head of development.

 

Yee will lead the company's South San Francisco center and direct therapeutic development and clinical trials at the company. He reports to senior vice president of R&D Robert Booth.

 

Yee was most recently vice president of clinical and preclinical research for inflammatory and viral diseases at Roche Bioscience. There, he oversaw lead compound selection, toxicology, pharmacokinetics, regulatory affairs, clinical research and related activities.

 


 

Charles River Laboratories, a major supplier of specialty lab mice and biomedical research tools, promoted Real Renaud to executive vice president and general manager of worldwide research model products and services.

 

In this position, Renaud will oversee the company's transgenics business and its laboratory and research services division.

 

He has been with the company since 1964, and was named vice president and general manager of European and North American Animal Operations in 1996.

 


 

Etiologics, the Medical Research Council spinoff formed to commercialize mouse mutation technology, has hired Ian Kent to chair the new company.

 

Kent has chaired a variety of small UK biotech firms, including Roslin Bio-Med and the xenotransplantation company Imutran.

 

Etiologics is based in Oxford, UK.

 


 

Biogenhas hired Roche VP Whaijen Soo as senior vice president of medical research, the company said on Dec. 16.

 

Soo will oversee the company's medical research activities, and will report to the executive VP of R&D.

 

Soo was with Roche Global Development for 17 years, and was most recently vice president of clinical sciences. He was in charge of oncology, virology, genomics and bioinformatics.

 

Biogen is a publicly owned company based in Cambridge, Mass.

 


 

NuGEN Technologies said on Dec. 12 that it had added Salk Institute's Inder Verma to its board of directors.

 

Verma is an American Cancer Society Professor of Molecular Biology in Salk's Laboratory of Genetics and has an appointment at the University of California, San Diego.

 

He will assist the company as it works to commercialize its oligonucleotide amplification techniques, which NuGEN says can effectively amplify nanogram amounts of DNA and RNA. The company hopes to launch its first products early next year.

 


 

Los Alamos National Laboratory has appointed Thomas Meyer as director of its new Center for Homeland Security, the institute said on Dec. 9.

 

Meyer was most recently director of the Advanced Technologies office for the Defense Advanced Research Projects Agency (DARPA).

 

The new center will act as a liaison with the new federal Department of Homeland Security and with outside organizations looking for assistance in these matters. It will focus on radiological/nuclear research, the chemical and biological program and on the National Infrastructure and Simulation Center.

 


 

Promoted? Changing jobs? GenomeWeb wants to know. E-mail Kathleen McGowan at [email protected] to appear in PEOPLE, a roundup of personnel comings and goings in genomics, that appears every Wednesday.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.